Managing Refractory Ocular Surface Disease With Cryopreserved Amniotic Membrane Therapy
July 21st 2025Ahmad M. Fahmy, OD, FAAO, discusses how cryopreserved amniotic membrane therapy can effectively treat complex cases of refractory ocular surface disease by addressing multiple contributing factors simultaneously, as demonstrated in a patient aged 81 years with diabetes, eczema, and severe blepharitis who showed significant epithelial improvement after comprehensive treatment.
Cryopreserved vs Dehydrated Amniotic Membranes
July 21st 2025Ahmad M. Fahmy, OD, FAAO, discusses how cryopreserved amniotic membranes preserve the critical heavy chain hyaluronic acid and pentaxin-3 molecules that deliver anti-inflammatory and antiscarring properties, making them significantly more effective than dehydrated versions for regenerating the ocular surface.
Advancing Dry Eye Management: Integrating Regenerative Therapies Into Optometric Practice
July 21st 2025Ahmad M. Fahmy, OD, FAAO, discusses how amniotic membranes can be effectively incorporated into optometric practice as a “reset button” treatment for the full continuum of ocular surface disease severity, from mild to severe cases. This offers patients an alternative to multiple eye drops while being efficiently applied during regular clinic visits.
AOA 2025: Innovation and education take forefront at Optometry's Meeting
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.
AOA 2025: A mental health primer for the optometric physician with Dr Nora Lee Cothran
Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.
AOA 2025: Companies sport their innovations at the Innovation Hub
Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.
AOA 2025: LNZ100 clinical trial insights from Dr Marc Bloomenstein
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
AOA 2025: A review of myopic retinal complications with Dr Carolyn Majcher
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
AOA 2025: Perfluorohexyloctane demonstrates early symptom relief and patient satisfaction
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
AOA 2025: New ways to fix old issues in scleral lenses
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
AOA 2025: An OD's guide to swollen nerves with Dr Mohammad Rafieetary
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
AOA 2025: Collaborative management of myopia from A to Z
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.